Eton Pharmaceutcials Inc Down 9.03% To $4.06 After Earnings Miss

Eton Pharmaceuticals Inc (ETON) missed earnings estimates for Q4 2023 this afternoon.

Eton Pharmaceutcials Inc's earnings came in at an EPS loss of $0.09 per share, 125% lower than estimates for an EPS loss of $0.04 per share. The firm's earnings are down 325% since reporting $0.04 per share in the same period a year ago.

Revenues were downbeat at $7.3 million. That represents a 13.94% decrease in revenues from the year-ago report and is 5.03% lower than consensus estimates set at $7.7 million.

The stock is down 9.03% to $4.06 after the report.

Eton Pharmaceutcials Inc's profit margins took a hit as earnings fell at a faster pace than revenues.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

InvestorsObserver gives the stock a Neutral Sentiment score at the moment based on recent trading.

Prior to the report, InvestorsObserver gave the stock an overall score of 54. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has a diversified pipeline of around eleven product candidates in various stages of development.